Baxter International Inc. (NYSE:BAX) Stock Has Consensus Target Price of $21.73 According to Brokerages

Shares of Baxter International Inc. (NYSE:BAX) have received a consensus recommendation of “Reduce” from the fourteen brokerages that are currently covering the firm, Marketbeat.com reports. Three equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and one has issued a buy rating on the company. The average 12 month target price among brokerages that have covered the stock in the last year is $21.73.

Several brokerages recently issued reports on BAX. Wall Street Zen downgraded shares of Baxter International from a “buy” rating to a “hold” rating in a report on Saturday, October 10th. Stifel Nicolaus increased their price target on Baxter International from $19.00 to $24.00 and gave the stock a “hold” rating in a research report on Tuesday, July 28th. Zacks Research upgraded Baxter International from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 11th. Citigroup reduced their price objective on Baxter International from $28.00 to $27.00 and set a “neutral” rating on the stock in a research note on Monday, October 5th. Finally, UBS Group boosted their price objective on Baxter International from $19.00 to $25.00 and gave the stock a “hold” rating in a research note on Tuesday, July 28th.

Baxter International Price Performance

BAX opened at $24.93 on Friday. The business has a 50 day moving average of $24.73 and a 200-day moving average of $21.32. Baxter International has a 1-year low of $15.73 and a 1-year high of $30.00.

Baxter International (NYSE:BAX) last issued its earnings results on Thursday, July 30th. The medical instruments supplier reported $0.56 EPS for the quarter, beating analysts’ consensus estimates of $0.37 by $0.19. The firm had revenue of $2.96 billion during the quarter, compared to analyst estimates of $2.80 billion. During the same quarter in the previous year, the company posted $0.59 earnings per share. The business’s revenue for the quarter was up 5.3% compared to the same quarter last year. Baxter International has set its FY 2026 guidance at 1.950-2.150 EPS. Equities research analysts predict that Baxter International will post 2.04 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Pzena Investment Management LLC bought a new stake in shares of Baxter International in the 2nd quarter worth $1,392,098,000. Tocqueville Asset Management L.P. purchased a new position in Baxter International during the second quarter worth about $30,604,000. BlackRock Inc. bought a new stake in Baxter International in the 2nd quarter worth about $1,744,874,000. AMG National Trust Bank purchased a new position in shares of Baxter International in the 2nd quarter worth approximately $2,522,000. Finally, Edmond DE Rothschild Holding S.A. purchased a new position in shares of Baxter International in the 2nd quarter worth approximately $51,958,000. 90.19% of the stock is currently owned by institutional investors.

Baxter International Company Profile

Baxter International Inc is a global medical products and healthcare technology company headquartered in Deerfield, Illinois. The company develops, manufactures and distributes products used in hospitals, clinics, ambulatory care centers and other healthcare settings.

Baxter’s portfolio has included intravenous therapies and administration systems, infusion pumps, connected-care technologies, surgical products, patient monitoring equipment and products used in medication preparation and delivery.